Prestige Consumer Healthcare (PBH)
NYSE:PBH
Want to see PBH full AI Analyst Report?
Top Page
Prestige Consumer Healthcare
(NYSE:PBH)
Select Model
Select Model
Rating:68Neutral
Price Target:
$51.00
▼(-12.27% Downside)
Action:Reiterated
Date:06/17/26
PBH scores as moderately attractive due to strong cash generation and solid post-2023 profitability, supported by a reasonable P/E valuation. The score is held back by weak technical momentum (price below key moving averages with negative MACD) and a balanced near-term outlook given supply-chain execution risk and higher leverage associated with acquisitions.
Positive Factors
Free Cash Flow Generation
Consistent operating cash flow (~$230M–$260M historically) and FCF that closely tracks earnings provide durable internal funding for acquisitions, buybacks, deleveraging and reinvestment. Reliable cash conversion improves strategic optionality and reduces reliance on external financing over the medium term.
Negative Factors
Top‑line Weakness
Recurring flat to declining organic revenue and a fiscal '26 revenue decline highlight limited underlying category growth and exposure to timing/operational hits. This reduces operating leverage and means the company must rely on acquisitions or sustained execution improvements to restore multi‑year organic growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Generation
Consistent operating cash flow (~$230M–$260M historically) and FCF that closely tracks earnings provide durable internal funding for acquisitions, buybacks, deleveraging and reinvestment. Reliable cash conversion improves strategic optionality and reduces reliance on external financing over the medium term.
Read all positive factors
Prestige Consumer Healthcare (PBH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.24B
Dividend YieldN/A
Average Volume (3M)783.95K
Price to Earnings (P/E)12.0
Beta (1Y)0.35
Revenue Growth-4.31%
EPS Growth-8.94%
CountryUS
Employees600
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)3.94
Shares Outstanding47,372,166
10 Day Avg. Volume630,153
30 Day Avg. Volume783,950
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.30
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda9.57
Forecast
1Y Price Target
$72.00Price Target Upside23.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)4.54
Revenue Forecast (FY)$1.19B
Prestige Consumer Healthcare Business Overview & Revenue Model
Company Description
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The compan...
How the Company Makes Money
PBH makes money primarily by selling branded consumer healthcare products (mainly OTC medications and related health items) to retailers, wholesalers, and distributors. Revenue is generated when PBH ships finished goods under its brands into retai...
Prestige Consumer Healthcare Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
Balanced: the call highlighted strong cash generation, margin resilience, strategic M&A (Pillar5, Breathe Right, LaCorium) and digital/channel strengths (e‑commerce ~18%), which position the company for medium‑term upside. However, significant near‑term execution risks—chiefly Clear Eyes supply disruptions, production ramp uncertainty, and shipping disruptions from geopolitical events—drove fiscal '26 revenue declines and create short‑term volatility. Management provided cautious fiscal '27 guidance that assumes improvement in the back half of the year and emphasized deleveraging after acquisitions.Positive Updates
Strong Free Cash Flow Generation
Generated $246.4M in free cash flow for fiscal '26, up ~1.3% year-over-year; company expects >= $250M in free cash flow for fiscal '27 and projects cumulative cash flow approaching $900M over the next 3 years (preliminary, excluding pending acquisitions).
Negative Updates
Clear Eyes Supply Chain Disruption
Clear Eyes production shutdowns, delayed shipments and extended maintenance/upgrade downtime at Pillar5 materially weighed on sales; Clear Eyes was a primary driver of the fiscal '26 decline and created volatility into Q1 of fiscal '27.
Read all updates
Q4-2026 Updates
Positive
Negative
Strong Free Cash Flow Generation
Generated $246.4M in free cash flow for fiscal '26, up ~1.3% year-over-year; company expects >= $250M in free cash flow for fiscal '27 and projects cumulative cash flow approaching $900M over the next 3 years (preliminary, excluding pending acquisitions).
Read all positive updates
Company Guidance
For fiscal 2027 Prestige is guiding to revenues of $1.10–$1.12 billion with organic growth of roughly 1–3%, adjusted EPS of $4.42–$4.51, and Q1 revenue of about $250 million with Q1 adjusted EPS of ~$0.87; adjusted gross margin is expected to be roughly flat to FY26 (FY26: 55.6%), advertising & marketing above 13% of sales (FY26: 13.7%), adjusted G&A about 10.5% of sales with Q1 G&A ~ $30 million, CapEx ~ $25 million, and free cash flow of $250 million or more (FY26 FCF $246.4 million). The balance sheet at March 31 showed net debt of ~ $900 million and covenant leverage of 2.6x; management expects cumulative cash flow over the next three years (including pending acquisitions) to approach $900 million, intends to deleverage toward ~3x after closing Breathe Right and LaCorium, and retains >$90 million of share‑repurchase authorization (after >$150 million repurchased in FY26). Pending deals: Breathe Right ~>$125 million of revenue and was previously estimated to be ~+$0.25 EPS (annualized) and LaCorium ~>$40 million of revenue with ~ $12 million run‑rate EBITDA when fully integrated. Guidance embeds continued oil‑related inflation and diesel cost pressure to be offset by cost actions and tactical pricing; management expects eye care production to meaningfully ramp in the back half of FY27, sees a path to a ~10% revenue CAGR through FY29 (organic long‑term 2–3%), low‑to‑mid‑30s EBITDA margins, and an EPS CAGR of ~8%+ to FY29.Prestige Consumer Healthcare Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
79
Positive
Cash Flow
82
Very Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.09B | 1.14B | 1.13B | 1.13B | 1.09B |
| Gross Profit | 574.64M | 634.46M | 624.45M | 625.29M | 620.65M |
| EBITDA | 331.11M | 361.99M | 373.86M | 7.87M | 358.84M |
| Net Income | 190.30M | 214.60M | 209.34M | -82.31M | 205.38M |
Balance Sheet | |||||
| Total Assets | 3.55B | 3.40B | 3.32B | 3.35B | 3.67B |
| Cash, Cash Equivalents and Short-Term Investments | 63.87M | 97.88M | 46.47M | 58.49M | 27.18M |
| Total Debt | 1.05B | 1.04B | 1.14B | 1.37B | 1.51B |
| Total Liabilities | 1.66B | 1.57B | 1.66B | 1.91B | 2.09B |
| Stockholders Equity | 1.89B | 1.83B | 1.66B | 1.45B | 1.58B |
Cash Flow | |||||
| Free Cash Flow | 254.23M | 243.29M | 239.38M | 221.93M | 250.28M |
| Operating Cash Flow | 265.41M | 251.51M | 248.93M | 229.72M | 259.92M |
| Investing Cash Flow | -136.84M | -17.45M | -20.11M | -11.58M | -256.51M |
| Financing Cash Flow | -163.84M | -182.07M | -241.01M | -185.85M | -7.57M |
Prestige Consumer Healthcare Technical Analysis
Neutral
58.13
Price Trends
50.76
Negative
57.10
Negative
59.66
Negative
Market Momentum
-0.98
Negative
46.18
Neutral
38.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Neutral. The current price of 58.13 is above the 20-day moving average (MA) of 47.00, above the 50-day MA of 50.76, and below the 200-day MA of 59.66, indicating a neutral trend. The MACD of -0.98 indicates Negative momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 38.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PBH.
Prestige Consumer Healthcare Risk Analysis
Prestige Consumer Healthcare disclosed 25 risk factors in its most recent earnings report. Prestige Consumer Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prestige Consumer Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $2.46B | 45.74 | 27.21% | ― | 13.54% | ― | |
68 Neutral | $2.24B | 11.97 | 10.29% | ― | -4.31% | -8.94% | |
66 Neutral | $89.43B | 19.77 | -265.44% | 0.37% | 12.36% | 48.80% | |
63 Neutral | $54.98B | 35.79 | -55.72% | 0.98% | 12.80% | 2.04% | |
60 Neutral | $9.53B | 25.06 | 11.86% | ― | 5.64% | 2.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PBH
Prestige Consumer Healthcare
47.18
-33.97
-41.86%
CAH
Cardinal Health
234.75
70.99
43.35%
HSIC
Henry Schein
83.69
10.54
14.41%
MCK
McKesson
763.81
44.74
6.22%
GRDN
Guardian Pharmacy Services, Inc. Class A
38.88
17.73
83.83%
Prestige Consumer Healthcare Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Prestige Consumer Healthcare Completes Breathe Right Brand Acquisition
Positive
Jun 16, 2026
Prestige Consumer Healthcare Inc. completed the acquisition of the Breathe Right brand and certain other brands from Foundation Consumer Healthcare on June 12, 2026, for $1.045 billion in cash, or about $900 million net of anticipated tax benefits...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Prestige Consumer Healthcare Issues Fiscal 2026 Results, Outlook
Positive
May 13, 2026
On May 10, 2026, Prestige’s Australian subsidiaries agreed to acquire all shares of LaCorium Health group entities, a leader in Australian therapeutic skin care, from a group of sellers for about $150 million in cash, with closing expected i...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Prestige Consumer to Acquire Breathe Right Brand Portfolio
Positive
Mar 20, 2026
On March 19, 2026, Prestige Brands, Inc., a wholly owned unit of Prestige Consumer Healthcare, signed an asset purchase agreement to acquire from Foundation Consumer Brands a portfolio of over-the-counter health products centered on Breathe Right ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.